Myocardial postconditioning is lost in vascular nitrate tolerance

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 3, 2013, Pages 298-303

  Fekete, Veronika ^a   Murlasits, Zsolt ^b   Aypar, Eda ^a   Bencsik, Péter ^b   Sárközy, Márta ^a   Szénási, Gábor ^c   Ferdinandy, Péter ^b,c   Csont, Tamás ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PHARMAHUNGARY GROUP   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Infarct size; Nitrate tolerance; Nitroglycerin; Postconditioning; RISK pathway; Survival kinase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; MALE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; WISTAR RAT;

ANIMALS; CORONARY CIRCULATION; CORONARY VESSELS; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HEART; ISCHEMIC POSTCONDITIONING; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; NITROGLYCERIN; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 84884669044     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182993ae0     Document Type: Article

References (42)

1. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418-458
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136
3. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: Preconditioning and postconditioning. Cardiovasc Res. 2009;83: 234-246
4. Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol. 2009;296:H1705-H1720
5. Skyschally A, van Caster P, Iliodromitis EK, et al. Ischemic postconditioning: Experimental models and protocol algorithms. Basic Res Cardiol. 2009;104:469-483
6. Balakumar P, Rohilla A, Singh M. Pre-conditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: What could be the next footstep? Pharmacol Res. 2008;57:403-412
7. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost. 2009;101:626-634
8. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006;70:240-253
9. Kupai K, Csonka C, Fekete V, et al. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: Role of peroxynitrite. Am J Physiol Heart Circ Physiol. 2009;297:H1729-H1735
10. Przyklenk K, Maynard M, Greiner DL, et al. Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type- 1 diabetes. Antioxid Redox Signal. 2011;14:781-790
11. Kocsis GF, Pipis J, Fekete V, et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol. 2008;294:H2406-H2409
12. Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol Ther. 2005;105:57-68
13. Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev. 2010;18:190-197
14. Szilvassy Z, Ferdinandy P, Nagy I, et al. The effect of continuous versus intermittent treatment with transdermal nitroglycerin on pacing-induced preconditioning in conscious rabbits. Br J Pharmacol. 1997;121:491-496
15. Fan Q, Gao F, Zhang L, et al. Nitrate tolerance aggravates postischemic myocardial apoptosis and impairs cardiac functional recovery after ischemia. Apoptosis. 2005;10:1235-1242
16. Gori T, Dragoni S, Di Stolfo G, et al. Tolerance to nitroglycerin-induced preconditioning of the endothelium: A human in vivo study. Am J Physiol Heart Circ Physiol. 2010;298:H340-H345
17. Csont T. Nitroglycerin-induced preconditioning: Interaction with nitrate tolerance. Am J Physiol Heart Circ Physiol. 2010;298:H308-H309
18. Csont T, Csonka C, Onody A, et al. Nitrate tolerance does not increase production of peroxynitrite in the heart. Am J Physiol Heart Circ Physiol. 2002;283:H69-H76
19. Csont T, Pali T, Szilvassy Z, et al. Lack of correlation between myocardial nitric oxide and cyclic guanosine monophosphate content in both nitrate-tolerant and -nontolerant rats. Biochem Pharmacol. 1998;56: 1139-1144
20. Csont T, Szilvassy Z, Fulop F, et al. Direct myocardial anti-ischaemic effect of GTN in both nitrate-tolerant and nontolerant rats: A cyclic GMPindependent activation of KATP. Br J Pharmacol. 1999;128:1427-1434
21. Bencsik P, Kupai K, Giricz Z, et al. Role of iNOS and peroxynitritematrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol Heart Circ Physiol. 2010;299:H512-H518
22. Turan N, Csonka C, Csont T, et al. The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts. Cardiovasc Res. 2006;70:384-390
23. Csonka C, Kupai K, Kocsis GF, et al. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010;61:163-170
24. Bouhidel O, Pons S, Souktani R, et al. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295:H1580-H1586
25. Gorbe A, Giricz Z, Szunyog A, et al. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol. 2010;105:643-650
26. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology, Cardiovasc Res. 2010;87:406-423
27. Iliodromitis EK, Zoga A, Vrettou A, et al. The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. Atherosclerosis. 2006;188:356-362
28. Hill M, Takano H, Tang XL, et al. Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. Circulation. 2001;104:694-699
29. Ambrosio G, Del Pinto M, Tritto I, et al GRACE Investigators. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: Insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31:430-438
30. Tsang A, Hausenloy DJ, Mocanu MM, et al. Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95:230-232
31. Bopassa JC, Ferrera R, Gateau-Roesch O, et al. PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res. 2006;69:178-185
32. Yang XM, Philipp S, Downey JM, et al. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol. 2005;100:57-63
33. Darling CE, Jiang R, Maynard M, et al. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: Role of ERK1/ 2. Am J Physiol Heart Circ Physiol. 2005;289:H1618-H1626
34. Gonon AT, Jung C, Yang J, et al. The combination of L-arginine and ischemic postconditioning at the onset of reperfusion limits myocardial injury in the pig. Acta Physiol (Oxf). 2011;201:219-226
35. Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs: No causal role for RISK activation. Circ Res. 2009;104:15-18
36. Lecour S. Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK path? J Mol Cell Cardiol. 2009;47:32-40
37. Goodman MD, Koch SE, Fuller-Bicer GA, et al. Regulating RISK: A role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol. 2008;295:H1649-H1656
38. Boengler K, Buechert A, Heinen Y, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res. 2008;102:131-135
39. Thielmann M, Dörge H, Martin C, et al. Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha and sphingosine. Circ Res. 2002;90:807-813
40. Zatta AJ, Kin H, Lee G, et al. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res. 2006;70:315-324
41. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia/reperfusion: Opportunities and obstacles for survival signaling. Br J Pharmacol. 2007;152:855-869
42. Romero-Perez D, Fricovsky E, Yamasaki KG, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008;52:1086-1094